Home » OXFORD BIOMEDICA PLC ANNOUNCES AWARDED RESEARCH GRANT
OXFORD BIOMEDICA PLC ANNOUNCES AWARDED RESEARCH GRANT
July 27, 2005
Oxford BioMedica (LSE: OXB), the leading gene therapy company, announced today that the UK Motor Neurone Disease (MND) Association has awarded a research grant to support preclinical evaluation of MoNuDin for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease. The grant is initially for £350,000, which will fund a key preclinical efficacy study and support preparations for clinical trials. The Company is targeting the start of clinical development in 2006-07.
Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=91549)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct